Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFβ/MYH11 transcript

Haematologica

Volumn 85, Issue 5, 2000, Pages 552-554

  Martinelli, Giovanni ^a,b   Ottaviani, Emanuela ^a   Testoni, Nicoletta ^a   Montefusco, Vittorio ^a   Buonamici, Silvia ^a   Tura, Sante ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROGNOSIS;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 16; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INVERSION, CHROMOSOME; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0033932857     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Mandelli F, Petti MC, Lo Coco F. Therapy of acute myeloid leukemia: cowards a patient-oriented, risk-adapted approach. Haematologica 1998; 83:1015-23.
2. Martinelli G, Ottaviani E, Testoni N, Visani G, Pagliani G, Tura S. Molecular analysis of granulocytic sarcoma: a single center experience. Haematologica 1999; 84: 380-2.
3. Liu P, Hajra A, Wijmenga C, et al. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood 1995; 85: 2289-302.
4. Testoni N, Lemoli RM, Martinelli G, et al. Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods Bone Marrow Transplant 1998; 22:1065-70.
5. Marcucci G, Caligiuri MA, Bloomfield CD. Defining the absence of the CBFβ/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions. Blood 1997; 90:5022-4.
6. Costello R, Sainty D, Blaise D, et al. Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBFβ/MYH11-positive acute myeloblastic leukemia. Blood 1997; 89:2222-3.
7. Evans PA, Short MA, Jack AS, et al. Detection and quantitation of the CBFβ/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML. Leukemia 1997; 11: 364-9.
8. Laczika K, Novak M, Hilgarth B, et al. Competitive CBFβ/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study. J Clin Oncol 1998; 16:1519-25.
9. Marcucci G, Livak KJ, Bi W, et al. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 1998; 12:1482-9.
10. Martinelli G, Saglio G, Baccarani M, et al. The use of quantitative RT-PCR for bcr-abl in the clinical management of chronic myeloid leukemia. Haematologica 1998; 83(e-suppl. 12):18-25.